Omeros (NASDAQ:OMER) Shares Gap Down Following Analyst Downgrade

Posted by on Jun 26th, 2026

Omeros Corporation (NASDAQ:OMER – Get Free Report) gapped down prior to trading on Friday after HC Wainwright lowered their price target on the stock from $40.00 to $33.00. The stock had previously closed at $10.72, but opened at $7.59. HC Wainwright currently has a buy rating on the stock. Omeros shares last traded at $8.6230, with a volume of 1,928,167 shares changing hands.

OMER has been the topic of a number of other reports. Wall Street Zen downgraded shares of Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Weiss Ratings lowered Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, June 2nd. Finally, D. Boral Capital restated a “buy” rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, April 21st. Two research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Omeros currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Check Out Our Latest Report on OMER

Insider Activity at Omeros

In related news, Director Thomas J. Cable sold 7,500 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $11.61, for a total transaction of $87,075.00. Following the sale, the director directly owned 35,067 shares in the company, valued at approximately $407,127.87. This represents a 17.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.50% of the company’s stock.

Hedge Funds Weigh In On Omeros

Large investors have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new stake in Omeros during the 1st quarter worth about $357,000. XTX Topco Ltd acquired a new stake in shares of Omeros during the 2nd quarter worth about $191,000. Invesco Ltd. raised its position in shares of Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 29,644 shares in the last quarter. Marshall Wace LLP lifted its stake in Omeros by 15.1% during the second quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after purchasing an additional 97,224 shares during the last quarter. Finally, Sei Investments Co. purchased a new stake in Omeros during the second quarter worth approximately $40,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Stock Down 20.6%

The stock has a market capitalization of $616.03 million, a price-to-earnings ratio of 12.19 and a beta of 2.52. The stock has a fifty day moving average of $11.97 and a 200-day moving average of $11.88.

Omeros (NASDAQ:OMER – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million for the quarter, compared to analyst estimates of $4.19 million. On average, equities analysts forecast that Omeros Corporation will post -0.94 EPS for the current fiscal year.

About Omeros

(Get Free Report)

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

See Also

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.